NervGen Pharma Appoints Adam Rogers as CEO
NervGen Pharma announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and CEO, effective immediately. "Following a thorough evaluation during Adam's tenure as Interim CEO, the Board concluded that his leadership has been defined by results," said Craig Thompson, Independent Director and Member of the Nominating and Corporate Governance Committee. "Adam exemplifies the leadership qualities that NervGen requires, bringing the unique perspective of a practicing physician and seasoned biotech executive who understands the complexities and discipline inherent in advancing a novel therapy such as NVG-291. His leadership reflects a commitment to all stakeholders, from patients, families, and advocates, to shareholders and employees, aligned around the shared objective of bringing NVG-291 to market as the first approved pharmacologic treatment for spinal cord injury."
